Form 4: Altimmune Director Granted 48,800 Stock Options

Altimmune, Inc. Director Teri L Lawver was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months.

Summary

• Teri L Lawver, a Director of Altimmune, Inc. (ALT), acquired 48,800 stock options.
• The options have an exercise price of $3.92 per share.
• The options begin vesting on September 25, 2025, in substantially equal monthly installments over 12 months.
• The options expire on September 25, 2035.
• The transaction was made pursuant to a Rule 10b5-1 plan, indicating a pre-arranged trading strategy.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event that aligns the director's interests with shareholders. It is generally viewed as a positive for corporate governance and incentivization, but it is not a significant operational or financial announcement.

Positives

• The grant of stock options aligns the interests of Director Teri L Lawver with those of shareholders, incentivizing long-term company performance.
• The exercise price of $3.92 per share suggests a future upside potential for the director if the stock price increases.

Negatives

• Potential for future dilution if the options are exercised, increasing the number of outstanding shares.

Future Outlook

The stock options will vest in substantially equal monthly installments over 12 months following September 25, 2025, contingent on the director's continued service. This indicates an expectation of continued tenure and contribution from the director.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including companies like Altimmune, Inc., to attract, retain, and incentivize key personnel by aligning their financial interests with long-term shareholder value creation. This compensation structure is widely used across publicly traded companies to foster a performance-driven culture.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• While the specific number of options (48,800) and exercise price ($3.92) are company-specific, the mechanism is comparable to compensation packages offered by peers such as Moderna (MRNA) or BioNTech (BNTX) for their non-executive directors, which often include equity components to align interests with long-term performance.
• Without specific peer compensation data, a direct quantitative comparison is limited, but the qualitative approach is consistent with industry norms.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased alignment between director and shareholder interests; minor potential for future dilution upon exercise of options.

Next Steps

• The options will vest monthly over the 12 months following September 25, 2025, subject to continued service.
• The director may choose to exercise vested options at any point before the expiration date of September 25, 2035.

Key Dates

Keywords

Altimmune, ALT, stock options, director compensation, insider transaction, Form 4, equity grant, vesting, 10b5-1 plan